Sentence: Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischaemia in ACS patients , most of whom were also receiving dual antiplatelet therapy with aspirin and clopidogrel .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['aspirin', 'clopidogrel'], 'is_context_needed': True}]